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  29 
Abstract 30 
 31 
Purpose: To examine whether muscle glycogen availability is associated with fatigue 32 
in a repeated exercise bout following short-term recovery.  33 
 34 
Methods: Ten endurance-trained individuals underwent two trials in a repeated 35 
measures design, each involving an initial run to exhaustion at 70%   (Run-1) 36 
followed by a 4-h recovery and a subsequent run to exhaustion at 70%   (Run-37 
2). A low-carbohydrate (L-CHO; 0.3 g·kg BM-1·h-1) or high-carbohydrate (H-CHO; 38 
1.2 g·kg BM-1·h-1) beverage was ingested at 30-min intervals during recovery. Muscle 39 
biopsies were taken upon cessation of Run-1, post-recovery and fatigue during Run-2 40 
in L-CHO (F2). In H-CHO, the muscle biopsies were obtained post-recovery, the time 41 
point coincident with fatigue in L-CHO (F2) and the point of fatigue during the 42 
subsequent exercise bout (F3). 43 
 44 
Results: Run-2 was more prolonged for every participant in H-CHO (80±16 min) 45 
than L-CHO (48±11 min; p< 0.001). Muscle glycogen concentrations were higher at 46 
the end of recovery in H-CHO (269±84 mmol·kg dm-1) versus L-CHO (157±37 47 
mmol·kg dm-1; p= 0.001). The rate of muscle glycogen degradation during Run-2 was 48 
higher in H-CHO (3.1±1.5 mmol·kg dm-1·min-1) than L-CHO (1.6±1.3 mmol·kg dm-49 
1·min-1; p= 0.05). The concentration of muscle glycogen was higher in H-CHO than 50 
L-CHO at F2 (123±28 mmol·kg dm-1; p< 0.01) but no differences were observed 51 
between treatments at the respective points of exhaustion (78±22 versus 72±21 52 
mmol·kg dm-1·min-1; H-CHO and L-CHO, respectively).  53 
 54 
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Conclusion: Increasing carbohydrate intake during short-term recovery accelerates 55 
glycogen repletion in previously exercised muscle and thus improves the capacity for 56 
repeated exercise. The availability of skeletal muscle glycogen is therefore an 57 
important factor in the restoration of endurance capacity because fatigue during 58 
repeated exercise is associated with a critically low absolute muscle glycogen 59 
concentration.  60 
 61 
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  63 
Introduction  64 
Endurance capacity during an initial prolonged exercise bout is primarily reliant upon 65 
pre-exercise glycogen availability, such that muscle glycogen content exhibits a direct 66 
positive correlation with exercise time to exhaustion (6, 34, 36). Similarly, muscle 67 
glycogen repletion can impact the time required to recover functional capacity, with 68 
carbohydrate intake accelerating both glycogen resynthesis and restoration of exercise 69 
capacity relative to when no carbohydrate is ingested (16, 17, 23). Furthermore, 70 
carbohydrate ingestion rate exhibits a dose-dependent relationship with the rate of 71 
muscle glycogen resynthesis until a threshold of ingesting ≈1.2 g·kg BM-1·h-1 (8). It is 72 
therefore logical to postulate that increasing carbohydrate intakes might also exhibit a 73 
dose-dependent relationship with the restoration of exercise capacity following short-74 
term recovery. However, while some information is available pertaining to muscle 75 
glycogen metabolism during a subsequent exercise bout (4, 9, 35), it remains merely 76 
an assumption that muscle glycogen availability is an important determinant of 77 
fatigue during a second bout of exercise following short-term recovery.  78 
 79 
Based on the few studies to have examined the relationship between carbohydrate 80 
ingestion rate in recovery and restoration of exercise capacity, most report no 81 
consistent pattern (7, 15, 41), with only one reporting a dose-dependent relationship 82 
(7). Notwithstanding that the aforementioned studies did not provide any glycogen 83 
data, there is some evidence that glycogen resynthesis (in particular liver glycogen) is 84 
an important determinant of endurance capacity following short-term recovery (10). 85 
This is understandable given that liver glycogen content is preferentially 86 
resynthesized over muscle glycogen when modest amounts of carbohydrate (≈0.3 87 
g·kg BM-1·h-1) are ingested following an initial exhaustive exercise bout (10). 88 
Conversely, the capacity for repeated exercise has also been dissociated from skeletal 89 
muscle glycogen availability in other studies (4, 7, 9). It is therefore possible that 90 
fatigue during repeated exercise may manifest differently from an initial prolonged 91 
exercise bout, and the availability of muscle glycogen may not be the primary cause 92 
of fatigue during subsequent exercise under all conditions. Accordingly, there is an 93 
outstanding need for improved understanding about the relative importance of muscle 94 
glycogen availability in offsetting fatigue during a repeated exercise bout as opposed 95 
to an initial bout, with implications for the optimal carbohydrate feeding strategy in 96 
recovery to maximize not only glycogen resynthesis but also restoration of exercise 97 
capacity.   98 
 99 
To this end, the current study nutritionally manipulated carbohydrate availability 100 
during short-term recovery to examine metabolic and ergogenic outcomes during 101 
subsequent exercise. Specifically, we sought to examine whether muscle glycogen 102 
availability is associated with fatigue in a repeated exercise bout following short-term 103 
recovery. Comparisons were therefore made between a low-carbohydrate (L-CHO) 104 
supplement sufficient only to restore hepatic glycogen with minimal rates of muscle 105 
glycogen resynthesis (10), and a high-carbohydrate (H-CHO) supplement designed to 106 
elicit high rates of muscle glycogen resynthesis (37). It was hypothesized that the 107 
extended run time to fatigue expected with increasing carbohydrate intake would be 108 
explained by a proportional acceleration of muscle glycogen resysnthesis during 109 
recovery and thus greater glycogen availability during repeated exercise.  110 
  111 
Materials and Methods 112 
Participants 113 
Nine healthy recreationally active men and one woman participated in the study. The 114 
characteristics of this sample were: age 21 ± 1 years; body mass (BM) 72.5 ± 8.2 kg; 115 
height 180 ± 9 cm;  61 ± 6 ml·kg-1·min-1; weekly exercise duration 5 ± 3 h. 116 
The participants were informed about the possible risks and discomforts involved 117 
before giving their voluntary consent to take part. The current study has been 118 
approved by the local National Health Services Research Ethics Committee (Ref: 119 
09/H0101/82) with a controlled clinical trial number: ISRCTN87937960.  120 
   121 
Preliminary measurements 122 
Participants undertook preliminary testing on two separate occasions. The first 123 
preliminary visit included the determination of each participant’s submaximal ( ) 124 
and maximal ( ) oxygen uptakes (31) on a motorized treadmill (Ergo ELG70, 125 
Woodway, Weil am Rhein, Germany). The data acquired from these tests were then 126 
employed to calculate the treadmill speeds that elicit 60 % and 70 % of . The 127 
second visit (familiarization trial) was completed at least two weeks prior to the main 128 
trials and required each participant to undergo the exercise protocol used in the main 129 
trials (described below) without any tissue or venous blood collection, and 130 
participants only ingested water at similar intervals to nutrient provision during the 131 
main trials (Figure 1). This trial was aimed to accustom the participants to the 132 
experimental procedures and apparatus in addition to fully familiarize with running to 133 
the point of volitional exhaustion and thereby diminish any learning/trial-order effects 134 
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(Run-1 and Run-2 times to exhaustion were 103 ± 17 min and 36 ± 9 min, 135 
respectively). Expired gas samples were collected during this visit to confirm the 136 
estimated relative speeds that corresponded to the required intensity during the main 137 
trials, with any adjustments applied accordingly.  138 
 139 
Experimental design  140 
Each participant performed two main trials in a repeated measures experimental 141 
design interspersed by an interval of ≥ 2 weeks. A weighed dietary record was 142 
completed 48 h preceding the familiarization trial, and was subsequently repeated 143 
prior to the commencement of the main trials (2638 ± 708 kcal·d-1; 55 ± 5 % 144 
carbohydrate; 17 ± 3 % fat; 28 ± 4 % protein). Participants were provided with a 145 
standardized meal (760 kcal; 57 % carbohydrate; 24 % Protein; 19 % fat) in the 146 
evening (12 ± 1 h) before the familiarization trial and replicated this prior to each 147 
main trial. Participants were also requested to abstain from alcohol consumption and 148 
refrain from strenuous physical activity for 48 h pre-trial, with any light exercise 149 
recorded and matched during the period of standardization of lifestyle for ensuing 150 
trials. 151 
 152 
 The main trials required participants to run to the point of volitional exhaustion (Run-153 
1) at an intensity of 70 % followed by a 4 h recovery period, where 154 
participants ingested a low carbohydrate (L-CHO) or a high carbohydrate (H-CHO) 155 
supplement. Following recovery, a second run to exhaustion (Run-2) at the same 156 
exercise intensity (i.e. 70 % ) was undertaken by each participant to assess 157 
restoration of exercise capacity. As has been successfully applied in previous studies 158 
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that have contrasted relative and absolute fatigue points to understand fatigue 159 
mechanisms in relation to running (34) and cycling (12), trial order required L-CHO 160 
to be completed first. Previous data (7) has reported that the restoration of exercise 161 
capacity can be dose-dependent with ingestion of moderate-high versus high 162 
carbohydrate during short-term recovery. Differences in exercise time to exhaustion 163 
can therefore be confidently expected between the more markedly different very low 164 
versus high carbohydrate doses in this study. Accordingly, establishing the absolute 165 
time-point of fatigue in L-CHO trials prior to H-CHO trials enables comparisons in 166 
the metabolic environment both at the point of volitional fatigue in both treatments 167 
and at the time point in the H-CHO treatment that corresponds to fatigue during L-168 
CHO treatment.  169 
 170 
Consistent with the above rationale, muscle biopsy samples were obtained in L-CHO 171 
trial: upon cessation of Run-1; post-recovery; and volitional exhaustion during Run-2 172 
(F2). In the H-CHO trial, the three muscle biopsy samples were obtained: post-173 
recovery; the time point coincident with fatigue in L-CHO (F2); and the point of 174 
volitional exhaustion during the subsequent exercise bout (F3). As a result of the 175 
dietary and activity standardization, and the fact the participants ran to the point of 176 
volitional exhaustion, negligible intra-individual variability in muscle glycogen levels 177 
following Run-1 were expected between trials, as previously reported in a similar 178 
protocol (34) and this was further verified by the well-matched times to exhaustion 179 
during Run-1 in both trials (results section). Thus, the sample obtained following 180 
Run-1 in L-CHO merely serves to verify the expected substantial glycogen depletion 181 
from the exercise protocol, whilst the remaining samples across both trials inform the 182 
primary research questions pertaining to differences in muscle glycogen availability 183 
immediately prior to and during the second exercise bout.   184 
 185 
Experimental protocol  186 
The experimental protocol pertaining to the current study is described in further detail 187 
elsewhere (1). Each participant arrived to the laboratory at 08:00 ± 1 h following an 188 
overnight fast (≥ 10 h). Upon arrival at the laboratory, participants completed a profile 189 
of mood state (POMS) questionnaire, before a baseline urine sample was obtained. 190 
Post-void nude body mass (BM) was then recorded (Weylux 424, UK) before a 5 min 191 
resting expired gas sample was collected using the Douglas bag technique. An 192 
indwelling cannula was inserted into an antecubital vein and a 10 ml baseline venous 193 
blood sample was collected.  Participants commenced the exercise protocol with a 194 
standardized 5 min warm-up at 60 % , where speed was then increased to 70% 195 
 
until the point of volitional exhaustion (11 ± 1 km·h-1). During Run-1, one 196 
minute expired gas samples, heart rate (HR; Polar FT2, Kempele, Finland), ratings of 197 
perceived exertion (RPE), and 10 ml blood samples were collected (Figure 1). Water 198 
intake was permitted ad libitum during the familiarization trial (0.5 ± 0.3 L during 199 
Run-1) and then matched for subsequent trials.  To accurately gauge relative levels of 200 
fatigue, participants were permitted to reduce the intensity (walking at 4.4 km·h-1) for 201 
2 min intervals on two occasions when they indicated that they could not maintain the 202 
prescribed intensity, followed by a return to the treadmill speed equivalent to 70 % 203 
.  Only on the third occasion that participants indicated that they were unable 204 
to run at the prescribed speed was volitional exhaustion accepted. Immediately 205 
following Run-1 in L-CHO trial, participants rested on an adjacent bed in a semi-206 
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supine position while ≈80 mg of muscle was obtained from the vastus lateralis by 207 
percutaneous needle biopsy technique (5) from a 3-5 mm incision made prior to 208 
exercise at the anterior aspect of the thigh using a surgical blade under local anesthetic 209 
(1 % lidocaine; Hameln Pharmaceuticals Ltd., Brockworth, UK). Thereafter, the first 210 
bolus of prescribed solution was immediately provided and recovery time 211 
commenced, before nude BM mass was recorded to assess hydration status through 212 
percentage change in mass (with body mass adjusted for the ingested bolus). The 213 
remaining seven aliquots of prescribed solution were provided at 30 min intervals 214 
(Figure 1). Participants were permitted 15 min to consume each volume, and 215 
subjective measures of stomach discomfort, gut fullness and thirst were recorded 216 
following the ingestion of each bolus using adapted Borg scales (1). Expired gas 217 
followed by venous blood samples were collected hourly prior to fluid provision. 218 
Furthermore, urine output was collected throughout the 4 h recovery period. 219 
Approximately 3 h 40 min into recovery, two (in L-CHO trial) or three (in H-CHO 220 
trial) 3-5 mm incisions were made proximally on the same leg at least 3 cm apart 221 
followed by obtaining a muscle biopsy sample at the end of recovery (with the 222 
remaining incisions dressed for easy access at later sampling points), with the order of 223 
dominant/non-dominant legs for muscle biopsy sampling being counterbalanced 224 
between the main trials. Nude BM was recorded at the end of recovery, and 225 
participants initiated a standardized warm-up before running at 70 %  
 
to 226 
volitional exhaustion. As for Run-1, water intake was permitted ad libitum during the 227 
familiarization trial and matched for subsequent trials (0.3 ± 0.3 L during Run-2). 228 
Reaching the point of volitional exhaustion was determined in an identical manner to 229 
the initial exercise bout. Expired gases, HR, RPE and venous blood samples were also 230 
collected during Run-2 (Figure 1). In the L-CHO trial fatigue was reached after 48 ± 231 
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11 min, at which point the one remaining incision site in that trial was used to obtain a 232 
final muscle biopsy. Therefore, after 48 ± 11 min in the subsequent H-CHO trial, the 233 
exercise protocol was briefly (624 ± 236 seconds) interrupted to obtain a muscle 234 
biopsy at the time point coincident with fatigue during L-CHO trial (i.e. F2) – thus 235 
permitting comparison of glycogen concentrations at a matched absolute time-point 236 
and rate of degradation over a matched period between the two nutritional 237 
interventions, as employed previously (34). Participants then mounted the treadmill 238 
and continued to run until volitional exhaustion before the final biopsy (i.e. F3) was 239 
obtained from the remaining incision site. BM was subsequently recorded following 240 
the attainment of the final biopsy from each participant. Ambient temperature and 241 
humidity were recorded at 60 min intervals throughout the trials using a portable 242 
weather station (WS 6730; Technoline, Berlin, Germany) and were not different 243 
among the trials: 20.3 ± 0.5 and 20.1 ± 0.5°C; and 46 ± 2 and 47 ± 2 % in L-CHO and 244 
H-CHO trials, respectively. Background music was standardized between trials and 245 
participants were unaware of the time elapsed during the exercise capacity test, with 246 
all verbal encouragement standardized.  247 
 248 
Solution composition 249 
The rates of carbohydrate (sucrose) intake in the L-CHO and H-CHO trials were 0.3 250 
g·kg BM-1·h-1 and 1.2 g·kg BM-1·h-1, equating to a total amount of carbohydrate 251 
provided during the recovery period of 87 ± 10 g and 349 ± 41 g in L-CHO and H-252 
CHO beverages, respectively. All treatment solutions were isovolumetric (10 ml·kg 253 
BM-1·h-1) relative to each participant’s BM (727 ± 86 ml·h-1), thus formulating a 3 % 254 
and 12 % solution in L-CHO and H-CHO respectively. Both supplements were 255 
matched for their electrolyte content (sodium and potassium) and were flavor 256 
matched. Full information pertaining to the nutritional treatments is provided 257 
elsewhere (1). Owing to the design of the experiment (i.e. participants were aware of 258 
the number of biopsies planned during each run), the treatments were not blinded. 259 
 260 
Blood analysis  261 
From each 10 ml venous blood sample, 5 ml was transferred into a non-anticoagulant 262 
tube and left to clot for ≈45-min at room temperature before being centrifuged at 2000 263 
xg for 10 min at 4ºC (Heraeus Primo R; Thermo Fisher Scientific, Loughborough, 264 
UK) for the analysis of serum insulin concentrations via enzyme-linked 265 
immunosorbent assay (ELISA; Mercodia, Uppsala, Sweden) using a 266 
spectrophotometric plate reader (Spectrostar Nano, BMG Labtech, Ortenberg, 267 
Germany). The remaining 5 ml of each blood sample was dispensed into a 268 
ethylenediaminetetraacetic acid (EDTA) treated tube and was immediately analyzed 269 
for hemoglobin (Sysmex SF-3000 Sysmex Ltd., Wymbush, UK) and hematocrit 270 
(Hawksley, Lancing, UK) concentrations for the determination of plasma volume 271 
changes throughout the trials (14). The remaining blood was then spun for 272 
centrifugation under 2000 xg for 10 min at 4ºC for the analysis of plasma glucose, 273 
non-esterified fatty acids, lactate and urea using a spectrophotometric analyzer (RX 274 
Daytona, Randox Laboratories Ltd., Crumlin, UK). 275 
 276 
Muscle analysis 277 
Each muscle sample was immediately extracted from the needle biopsy and snap-278 
frozen into liquid nitrogen, where it was subsequently dissected to remove 15-30 mg 279 
of muscle fragment prior to being placed in a freeze-dryer (Modulyo, Edwards, UK) 280 
for ≈18 hours at -50°C. After removal of visible blood and connective tissue, the 281 
freeze-dried muscle samples were then reduced to fine powder using an agate pestle 282 
and mortar and used for the extraction and determination of phosphocreatine (PCr), 283 
creatine (Cr) and muscle glycogen concentrations. The relative concentrations of 284 
these metabolites were determined in duplicate according to enzymatic methods 285 
previously described (18, 26, 34) using a spectrophotometric plate reader 286 
(SpectraMax 190, Molecular Devices, USA). Glycogen was assayed by hydrolysis in 287 
1 mol/l hydrochloric acid (HCl) and was determined both as acid-soluble and acid-288 
insoluble glycogen (22). The total mixed-muscle glycogen concentration was 289 
calculated by adding the acid-soluble and acid-insoluble glycogen concentrations. All 290 
muscle metabolites were adjusted to peak total Cr (PCr+Cr) for each subject to correct 291 
for variability in blood, connective tissue, and other non-muscle constituents between 292 
biopsies. Total glycogen concentrations are reported as mmol glucosyl units per 293 
kilogram of dry mass (mmol·kg dm-1) to account for any measurement error 294 
associated with fluid shift during exercise and rehydration. The contribution of muscle 295 
glycogen towards whole-body carbohydrate oxidation during Run-2 was estimated 296 
from lean tissue mass of all leg muscle (6 % of body mass) from a typical 72.1 kg 297 
trained individual using dual-energy X-ray absorptiometry (DXA) analysis (9). 298 
 299 
Expired gas analysis  300 
Expired gas samples were collected using the Douglas bag method (Hans Rudolph, 301 
Shawnee, KS, USA), and the relative oxygen and carbon dioxide factions were 302 
quantified by paramagnetic and infrared analyzers, respectively (Servomex, 303 
Crowborough, UK). The calculations of  and  were then used for the 304 
determination of carbohydrate and lipid oxidation rates (g·min-1) using stoichiometric 305 
formulae, assuming that the contribution of protein oxidation was negligible under 306 
those conditions (24): 307 
Carbohydrate Oxidation = (4.210 · ) - (2.962· )  308 
Fatty Acid Oxidation = (1.695 · ) - (1.701 · ) 309 
Extra-muscular carbohydrate oxidation was then derived from the difference between 310 
whole-body carbohydrate oxidation as determined from indirect calorimetry and 311 
intramuscular carbohydrate oxidation (overall muscle glycogen degradation rates).  312 
 313 
Urine analysis   314 
Baseline urine collection to determine hydration was assessed via freezing point 315 
depression method by using a cryoscopic osmometer (Advanced Instruments, Inc, 316 
Norwood, MA, USA ) and adequate hydration was assumed for osmolality values ≤ 317 
900 mOsm·kg-1 (30). During the 4 h recovery period, the voided urine was collected 318 
in a vessel for the determination of total urine output during recovery. 319 
 320 
POMS questionnaire  321 
On the day of each trial, before exercise, participants completed a 37-item short form 322 
profile of mood state (POMS-SF) questionnaire (28).  POMS-SF items are divided 323 
items into six categories: tension, depression, anger, fatigue, confusion and vigor. 324 
Total mood disturbance (TDM) was then calculated as the sum of the first five 325 
categories minus vigor. 326 
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 327 
Statistical analysis  328 
A priori sample size estimation was conducted based on the exercise capacity data of 329 
a similar previous study (7) which showed  that a sample size of n= 6 would provide 330 
90% power to detect a difference in exercise capacity of 16.2 min using a two-tailed t-331 
test between two carbohydrate supplements with differing amounts. Paired t-tests 332 
were used to analyze data involving a single comparison of two level means. Where 333 
paired-difference data were deemed non-normally distributed by Shaprio-Wilk test, 334 
values are reported as median (range), with Wilcoxon signed rank test being used to 335 
compare medians. A two-way linear mixed model with repeated measures (time x 336 
trial) was employed to identify overall differences between experimental conditions. 337 
Wherever a significant interaction effect was found, a Bonferroni step-wise correction 338 
was employed to determine the location of the variance (3). Pearson product moment 339 
correlation coefficient (r) was used to explore the relationship between muscle 340 
glycogen availability at the end of recovery and time to exhaustion during Run-2. 341 
Incremental area under the concentration curve (iAUC) for plasma glucose and serum 342 
insulin concentrations during the recovery were calculated using the method 343 
recommended by Wolever (40).  Statistical procedures were performed using 344 
commercially available software (IBM SPSS version 21.0, SPSS Inc., Chicago, IL) 345 
and significance was set at an alpha level of 0.05. Unless otherwise stated, all results 346 
were reported in text as the mean ± standard deviation (SD) of the mean and the error 347 
bars depicted in figures are confidence intervals (CI) that have been corrected to 348 
remove between-subject variance (25). 349 
 350 
Results  351 
Exercise capacity  352 
The run times to exhaustion in Run-1 (i.e. prior to intervention) were very well-353 
matched between treatments, with median time to exhaustion of 105 min (72-133 354 
min) in L-CHO trial and 105 min (75-161 min) in H-CHO trial (p= 0.12). All 355 
participants were able to run longer during the subsequent run when more 356 
carbohydrate had been ingested in recovery, with mean run times of 48 ± 11 min in L-357 
CHO and 80 ± 16 min in H-CHO (p< 0.001). Moreover, the magnitude of this pattern 358 
between treatments was consistent for every participant in the study (i.e. improvement 359 
of 31 ± 9 min), as represented in Figure 2.  360 
 361 
Relative exercise intensities were also successfully standardized between the 362 
experimental treatments and averaged 69 ± 1 %  in Run-1 and 69 ± 3 % 363 
 in Run-2 across both treatments. These were reflected by the overall heart 364 
rates of 169 ± 9 and 167 ± 9 beats·min-1 recorded during L-CHO and H-CHO, 365 
respectively.   366 
 367 
Muscle glycogen 368 
Figure 2 illustrates muscle glycogen concentrations across both treatments. A time x 369 
trial interaction was established for total muscle glycogen concentrations (F= 9.8; p= 370 
0.003) and accordingly there was greater muscle glycogen content at the end of 371 
recovery in H-CHO than L-CHO. Despite a higher rate of glycogen degradation 372 
during Run-2 in the H-CHO treatment (3.1 ± 1.5 mmol·kg dm-1·min-1), when 373 
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compared to the absolute fatigue time point in L-CHO trial (1.6 ± 1.3 mmol·kg dm-374 
1·min-1 (p= 0.05) the muscle glycogen concentration at F2 was still higher in the 375 
former trial (123 ± 28 mmol·kg dm-1 versus 72 ± 21 mmol·kg dm-1; p< 0.01). Muscle 376 
glycogen concentrations were reduced to similar levels at the point of volitional 377 
exhaustion in both trials (Figure 2). A significant correlation was established (r= 0.45; 378 
p= 0.045) between muscle glycogen content at the end of recovery and time to 379 
exhaustion during Run-2.  380 
 381 
Plasma glucose and NEFA  382 
A time x trial interaction was observed in plasma glucose during recovery (F= 8.65; 383 
p= 0.004; Figure 3), which was associated with a higher glycemic iAUC in H-CHO 384 
(299 ± 125 mmol·240 min·l-1) during recovery than L-CHO (180 ± 138 mmol·240 385 
min·l-1; p= 0.04). There were also notable differences during the subsequent run (F= 386 
5.63; p= 0.02), with slightly lower plasma glucose concentrations in H-CHO than L-387 
CHO in the initial 30 min of exercise. No frank hypoglycemia was observed at the 388 
point of fatigue in L-CHO (4.9 ± 1.1 mmol·l-1) or H-CHO (5.0 ± 0.9 mmol·l-1).  389 
 390 
Plasma NEFA concentrations were rapidly suppressed to basal levels during recovery 391 
in H-CHO while maintained at a relatively higher level in the L-CHO trial (treatment: 392 
p= 0.04). Upon commencement of the subsequent run, plasma NEFA were 393 
consistently elevated in L-CHO when compared to H-CHO (treatment: p< 0.001). An 394 
increase in NEFA concentrations from F2 to F3 was observed in H-CHO trial (p= 395 
0.008, Figure 4).  396 
 397 
Serum insulin 398 
Serum insulin concentrations were significantly higher during recovery when H-CHO 399 
was ingested as opposed to L-CHO (F= 9.0; p= 0.004; Figure 2). Accordingly, the 400 
insulinemic iAUC for the entire 4-h recovery period was elevated threefold when H-401 
CHO was ingested when compared to L-CHO (28 ± 12 versus 7 ± 3 nmol·240 min·l-1; 402 
p= 0.02).   403 
 404 
Plasma lactate and urea 405 
Plasma lactate concentrations declined during recovery in L-CHO but remained 406 
relatively elevated in H-CHO (time: p= 0.005). However, plasma lactate levels during 407 
the subsequent run (Figure 4) were not dissimilar between in L-CHO and H-CHO (2.5 408 
± 0.3 and 2.6 ± 0.2 mmol·l-1, respectively; p= 0.6). The plasma concentration of urea 409 
was not different between treatments and remained at basal levels throughout trials 410 
(5.6 ± 0.4 mmol·l-1 in both treatments).   411 
 412 
Substrate metabolism 413 
Whole-body carbohydrate and lipid oxidation rates were substantially different 414 
between treatments during Run-2 (F= 7.96; p= 0.006; Table 1). Although overall rates 415 
of metabolism during the repeated exercise bout were similar between treatments (L-416 
CHO = 64.9 kj·min-1; H-CHO = 66.7 kj·min-1), H-CHO ingestion resulted in lower 417 
lipid oxidation rates than L-CHO (4.3 ± 2.2 vs. 11.2 ± 3.5 mg·kg-1·min-1; p< 0.001) 418 
but higher rates of carbohydrate oxidation (44.5 ± 6.5 vs. 25.2 ± 9.3 mg·kg-1·min-1, 419 
respectively; p<0.001).  Figure 5 illustrates that the higher rates of whole body 420 
carbohydrate oxidation in H-CHO trial were likely attributable to variations in 421 
glycogen rather than extra-muscular carbohydrate metabolism (e.g. glucose and 422 
lactate), both at the point corresponding to fatigue with L-CHO (F2) and the point of 423 
absolute fatigue (F3).  424 
 425 
Hydration and subjective data 426 
Pre-exercise hydration status verified adequate fluid balance and was not different 427 
between treatments, as indicated by urine osmolality of 496 ± 316 and 540 ± 266 428 
mOsm.kg-1 in L-CHO and H-CHO, respectively (p= 0.5). Changes in BM were 429 
similar (p= 0.6) across both trials (-1.2 ± 0.6 and -1.3 ± 0.6 kg in L-CHO and H-CHO, 430 
respectively). The change in plasma volume was also similar (p= 0.9) between the 431 
respective treatments (2 ± 3 vs. 1.8 ± 3 %, respectively). The total urine produced 432 
during recovery was 1749 ± 840 ml in L-CHO and 1247 ± 613 ml in H-CHO trials 433 
(p= 0.09). There were no differences in any of the mood state categories in the 434 
POMS-SF (p> 0.05). A significant time x trial interaction was observed in RPE (F= 435 
6.38; p= 0.01); participants’ perceived effort was significantly lower in H-CHO than 436 
L-CHO from 15 min until F2 during Run-2 (p< 0.05). Subjective ratings of gut 437 
fullness, thirst, and stomach discomfort were similar between the experimental 438 
conditions (data not shown).  439 
 440 
Discussion 441 
The experimental design presented here provides novel insight regarding the role of 442 
muscle glycogen in fatigue by enabling both time- and fatigue-matched comparisons 443 
of substrate availability and utilization during the late stages of repeated exercise. 444 
Effective standardization of other relevant variables lends direct support to the 445 
hypothesis that muscle glycogen availability after recovery from prior exercise is 446 
indeed a primary determinant of subsequent exercise capacity. From a practical 447 
perspective, having utilized nutritional manipulation of carbohydrate availability to 448 
understand the role of glycogen, it can also therefore be concluded that carbohydrate 449 
ingestion can be employed to impact repeated exercise capacity via this mechanism.  450 
 451 
The improvement in subsequent endurance capacity with H-CHO treatment was 452 
clearly demonstrated by an increase of 31 ± 9 min relative to L-CHO, which is in 453 
agreement with one previous experiment (7) but in contrast with two others (15, 41). 454 
These discrepancies may be a consequence of a number of factors. The current study 455 
in addition to that of Betts et al. (7) included younger participants with higher  456 
than those used in previous investigations (15, 41). Furthermore, we employed a 457 
familiarization trial that was identical to the main experimental procedures. These 458 
measures may be an important distinction when considering that aerobically trained 459 
individuals who are familiarized with exercise capacity testing may be necessary to 460 
detect small, worthwhile intervention effects (19).  Moreover, subtle differences in the 461 
current experimental procedures may have contributed to accurately reaching true 462 
volitional exhaustion. Specifically, participants in the current experiment, as well as 463 
the only other study reporting a dose-dependent improvement in exercise capacity 464 
with carbohydrate ingestion (7), reduced the intensity on two occasions before fatigue 465 
was accepted. Indeed, participants were able to run for 10 ± 4 min from the first walk 466 
until the point of exhaustion in this study, enforcing the notion that volitional 467 
exhaustion may not have been achieved in previous investigations that did not allow 468 
these walks. Of course, other differences between protocols such as the precise type, 469 
max2OV

amount, and/or feeding frequency of the ingested carbohydrate offer possible 470 
alternative explanations (15, 41). 471 
 472 
Ingestion of 1.2 g sucrose·kg-1·h-1 markedly increased muscle glycogen availability 473 
compared to the relatively low quantity of sucrose (0.3 g·kg-1·h-1). This finding is 474 
consistent with most previous studies investigating muscle glycogen restoration with 475 
differing amounts of carbohydrate (8). In the current experiment, muscle glycogen 476 
utilization was accelerated with higher carbohydrate intake and thus glycogenolysis 477 
was shown to be proportional to muscle glycogen concentration, as has previously 478 
been determined (2, 29). Nevertheless, similar rates of muscle glycogen utilization 479 
were reported during a repeated exercise bout when differing amounts of 480 
carbohydrate were ingested during recovery (4, 35). The precise reasons for these 481 
apparently discrepant findings in relation to muscle glycogen utilization may be 482 
ascribed to the use of 13C-magnetic resonance spectroscopy by Berardi et al. (2006) to 483 
quantify muscle glycogen degradation (i.e. wider musculature versus biochemical 484 
analysis of <100 mg from the vastus lateralis; although these techniques correlate 485 
well (32)) and the type of exercise performed (i.e. cycling) that were dissimilar from 486 
the present study. Equally, the study by Tsintzas et al. (2003) employed treadmill 487 
running during a non-exhaustive exercise bout (15 min) and provided lower amounts 488 
of carbohydrate to the current experiment (0.15 g·kg-1·h-1 versus 0.53 g·kg-1·h-1). 489 
Concurrent with our finding that muscle glycogen concentrations were reduced to 490 
similar levels at the point of volitional exhaustion across both treatments, the current 491 
data suggest that muscle glycogen availability per se was associated with the 492 
improved restoration of endurance capacity with increased carbohydrate intake. 493 
 494 
When interpreting the ergogenic effect with H-CHO ingestion, it is important to 495 
consider the brief period where exercise was interrupted in this trial to obtain a muscle 496 
biopsy sample to compare glycogen utilization at this fatigue-matching point relative 497 
to L-CHO. Muscle glycogen restoration would occur at very low rates in the absence 498 
of carbohydrate feeding (≈0.5 mmol·kg dry mass-1·min-1 (21)). During a subsequent 499 
exercise bout at similar intensities, muscle glycogen utilization was estimated to be 500 
≈2.5 mmol·kg dry mass-1·min-1 during treadmill running (35). Thus, any resynthesis 501 
that may have occurred during the brief interruption period (624 ± 236 seconds) 502 
would theoretically account for only 2 min of extended exercise. Other possibilities 503 
that may have influenced subsequent exercise capacity in H-CHO treatment include 504 
knowledge of the treatment order and the psychological impact of resting period to 505 
obtain the muscle biopsy. Nevertheless, regarding the former, it was previously 506 
demonstrated that there was no placebo effect when carbohydrate was ingested during 507 
prolonged cycling, and that there was a clear ergogenic effect with carbohydrate 508 
intake relative to both a placebo and water ingestion (20). In relation to the 509 
psychological effect of the brief period to obtain the muscle sample, it was apparent 510 
that participants were able to continue exercising during H-CHO (RPE; 16 ± 1) 511 
relative to the fatigue-matching point (i.e. F2) in L-CHO (20 ± 0) and thus indicating 512 
that participants’ perceived effort was lower in H-CHO than L-CHO treatment before 513 
exercise was interrupted in H-CHO to obtain the final biopsy sample.  When 514 
considered collectively, it is reasonable to affirm that the short period to obtain a 515 
muscle sample is unlikely to explain the 65 % improvement in the capacity for 516 
subsequent exercise and that the imposed nutritional intervention may be ascribed for 517 
the ergogenic effect with H-CHO intake. 518 
 519 
The lowering of blood glucose was more prominent in H-CHO during the initial 30 520 
min of the subsequent run, likely reflecting a transient increase in leg glucose uptake 521 
and reduced liver glucose output secondary to the increase in insulin concentrations 522 
(27). Conversely, the relatively elevated plasma glucose concentrations early in 523 
exercise in the L-CHO trial likely reflect an increased hepatic glucose output, which is 524 
predominantly supported by an increased rate of hepatic glycogenolysis (38). Thus, 525 
the increased insulinemic response during recovery in H-CHO may have initially 526 
spared liver glycogenolysis such that glucose production to the active muscles was 527 
possible late in exercise. These physiological responses coupled with our finding of 528 
limited muscle glycogen restoration in L-CHO supports our prior assumption that the 529 
modest amounts of ingested carbohydrate will be largely sequestered by the liver due 530 
to highly efficient first pass hepatic extraction (10, 39). It is likely that liver glycogen 531 
resynthesis was augmented in both trials owing to the presence of fructose in the 532 
sucrose solutions (13) and thus the ongoing absorption of the ingested carbohydrate in 533 
H-CHO treatment is likely to contribute to the observed higher carbohydrate 534 
oxidation with this treatment. Indeed, both liver and muscle glycogen have an 535 
important role in restoration of subsequent endurance capacity (10). Therefore, it is 536 
not unreasonable to suggest that liver glycogen availability and increased exogenous 537 
carbohydrate oxidation may have contributed to the overall effect in the H-CHO 538 
treatment. Nonetheless, estimations of extra-muscular carbohydrate oxidation were 539 
not different between F2 and F3 in the H-CHO treatment (Figure 5). In conjunction 540 
with the observation of an increased glycogen utilization rate with H-CHO and that 541 
fatigue in both treatments coincided with depletion of muscle glycogen to critically 542 
low muscle glycogen concentrations, the current findings demonstrate that the 543 
availability of muscle glycogen is a primary determinant of fatigue during a repeated 544 
exercise bout following short-term recovery.      545 
 546 
Hypoglycemia and subsequent reduction in carbohydrate oxidation late in exercise 547 
have been proposed as a major cause of fatigue during prolonged moderate to high-548 
intensity cycling exercise (12). However, it has been consistently demonstrated that 549 
fatigue during prolonged moderate to high-intensity running is not associated with 550 
hypoglycemia (33, 34, 36). The latter notion was further supported by the current 551 
investigation, whereby fatigue was not associated with hypoglycemia in either 552 
treatment. Additionally, whilst carbohydrate oxidation during a repeated exercise bout 553 
was greater when higher amounts of carbohydrate (≈0.75 g·kg-1·h-1) were provided 554 
relative to a lower dose (≈0.25 g·kg-1·h-1) during recovery, no discernable differences 555 
in plasma glucose concentrations or time to exhaustion were shown (15). Indeed, 556 
fatigue during prolonged exercise was shown independent of carbohydrate oxidation 557 
or avoidance of hypoglycemia (11). Further support for the latter study comes from 558 
H-CHO trial in the present investigation, where neither hypoglycemia nor a decline in 559 
carbohydrate oxidation was apparent at the cessation of exercise to explain fatigue. 560 
Thus, it can be suggested that factors other than hypoglycemia or a decline in 561 
carbohydrate oxidation rates limited the capacity for subsequent exercise. 562 
 563 
In conclusion, the ingestion of 1.2 g·kg-1·h-1 of carbohydrate during 4 h recovery from 564 
an initial exhaustive exercise bout increased muscle glycogen availability prior to a 565 
repeated exercise bout when compared with the ingestion of 0.3 g·kg-1·h-1.  In 566 
concordance, the capacity for repeated exercise was improved in a dose-dependent 567 
manner. The rate of glycogen utilization was accelerated in the H-CHO trial during 568 
the repeated exercise bout and fatigue was associated with glycogen depletion to 569 
critically low levels in both treatments. The extended run time to fatigue expected 570 
with increasing carbohydrate intake is attributable to increased muscle glycogen 571 
repletion during recovery and therefore the availability of this substrate during Run-2.    572 
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Table 1. Substrate metabolism and respiratory exchange ratio (RER) during Run-1 and Run-2 with L-CHO or H-CHO treatments. 691 
Values are mean ± SD. *, values different between L-CHO and H-CHO (p< 0.05); #, values different at absolute fatigue (F2 vs. F3) 692 
between L-CHO and H-CHO (p<0.05) 693 
 Run-1   Run-2  
 Pre 30 min 60 min 90 min F1 15 min 30 min 45 min F2 60 min F3 
Carbohydrate 
oxidation 
(g·min-1) 
           
L-CHO 0.26±0.15 2.20±0.36 2.18±0.37 1.90 ±0.40 1.87±0.72  1.92±0.74 1.99±0.89 2.74±1.04 1.60±0.79   
      * *  *  # 
H-CHO 0.33±0.19 2.59±0.70 2.30±0.59  2.02±0.80 1.98±0.73 2.68±0.68 3.18±1.06 2.81±0.95 2.41±0.46 2.66±0.47 2.41±0.98 
Lipid 
oxidation 
(g·min-1) 
           
L-CHO 0.06±0.06 0.57±0.20 0.61±0.21 0.76±0.22 0.77±0.36 0.77±0.22 0.71±0.31 0.56±0.31 0.94±0.24   
      * *  *  # 
H-CHO 0.06±0.07 0.44±0.20 0.57±0.23 0.66±0.44 0.70±0.32 0.24±0.17 0.26±0.18 0.40±0.26 0.45±0.16 0.36±0.23 0.50±0.33 
RER            
L-CHO 0.87±0.12  0.89± 0.04 0.88±0.04 0.85±0.04 0.85±0.06 0.85±0.05 0.86±0.07 0.90±0.07 0.82±0.05   
      * *  *  # 
H-CHO 0.90±0.11 0.91±0.04 0.89±0.04 0.88±0.08 0.86±0.06 0.96±0.05 0.95±0.04 0.92±0.05 0.91±0.04 0.93±0.02 0.90±0.06 
 694 
Figure 1. A schematic representation of the study protocol †, body mass assessment; 695 
*, fluid provision; #, expired gas and blood sample;, muscle biopsy during L-CHO; 696 
, muscle biopsy during H-CHO; F1, fatigue in Run-1; F2, fatigue in L-CHO; F3, 697 
fatigue in H-CHO; dashed columns, warm-up; black column, run time to exhaustion 698 
in L-CHO trial; grey column, extended run time to exhaustion with H-CHO treatment 699 
during Run-2. 700 
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Figure 2-A. Muscle glycogen concentrations at the end of Run-1 (F1), at the end of 4 707 
h recovery, time to exhaustion with L-CHO treatment (F2) and time to exhaustion 708 
with H-CHO treatment (F3). Figure 2-B, mean and individual run times to exhaustion 709 
following the ingestion of L-CHO or H-CHO during 4 h recovery. Values are means 710 
± CI. *, values different between L-CHO and H-CHO (p< 0.01). #, values different 711 
between F2 and F3 within the H-CHO treatment (p< 0.01).  712 
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 715 
Figure 3. Plasma glucose and serum insulin concentrations during Run-1, recovery 716 
and Run-2 with L-CHO or H-CHO treatments. Values are mean ± CI. *, values 717 
different between L-CHO and H-CHO (p< 0.05). F1, time to exhaustion during Run-718 
1; F2, time to exhaustion with L-CHO treatment; F3= time to exhaustion with H-CHO 719 
treatment.  720 
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 722 
Figure 4. Plasma NEFA and lactate concentrations during Run-1, recovery and Run-2 723 
with L-CHO or H-CHO treatments. Values are mean ± CI. *, values different between 724 
L-CHO and H-CHO (p< 0.01). †, values different from F2 to F3 in H-CHO treatment. 725 
F1, time to exhaustion during Run-1; F2, time to exhaustion with L-CHO treatment; 726 
F3, time to exhaustion with H-CHO treatment. 727 
  728 
L - C H O H - C H O  ( F 2 ) H - C H O  ( F 3 )
0
1 0
2 0
3 0
4 0
5 0
6 0
7 0
8 0
S
u
b
s
t
r
a
t
e
 o
x
i
d
a
t
i
o
n
 d
u
r
i
n
g
 R
u
n
-
2
(
k
J
.m
i
n
-
1
)
L i p i d
E x t r a - m u s c u l a r  C H O
M u s c l e  G l y c o g e n
M u s c l e
g l y c o g e n
E x t r a - m u s c u l a r
C H O
E x t r a - m u s c u l a r
C H O
M u s c l e
g l y c o g e n
L i p i d
L i p i d
M u s c l e
g l y c o g e n
E x t r a - m u s c u l a r
C H O
L i p i d
 *  *
† 
729 
 730 
Figure 5. The contribution of muscle glycogen, extra-muscular carbohydrate (CHO) 731 
and lipids to total substrate metabolism (kJ·min-1) during Run-2 with L-CHO or H-732 
CHO treatments. *, Muscle glycogen values different between L-CHO and H-CHO 733 
(p< 0.05). †= lipid values different between L-CHO and H-CHO treatments. (p< 734 
0.05), F1, time to exhaustion during Run1; F2, time to exhaustion with L-CHO 735 
treatment; F3, time to exhaustion with H-CHO treatment. 736 
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